gabapentin has been researched along with Nociceptive Pain in 12 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Nociceptive Pain: Dull or sharp aching pain caused by stimulated NOCICEPTORS due to tissue injury, inflammation or diseases. It can be divided into somatic or tissue pain and VISCERAL PAIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The current study evaluated the pharmacological activity of gabapentin (GBP) and its salicylaldehyde derivative (gabapentsal; [2-(1-(((2-hydroxybenzylidene) amino) methyl) cyclohexyl) acetic acid]; GPS) in well-established mouse models of nociceptive pain, inflammatory edema, and pyrexia at doses of 25-100 mg/kg." | 8.02 | Pharmacological evaluation of the gabapentin salicylaldehyde derivative, gabapentsal, against tonic and phasic pain models, inflammation, and pyrexia. ( Ahmad, N; Akbar, S; Amin, MU; Islam, NU; Khurram, M; Sewell, RDE; Shahid, M; Subhan, F; Ullah, I; Ullah, N; Ullah, R, 2021) |
| " The current study evaluated the pharmacological activity of gabapentin (GBP) and its salicylaldehyde derivative (gabapentsal; [2-(1-(((2-hydroxybenzylidene) amino) methyl) cyclohexyl) acetic acid]; GPS) in well-established mouse models of nociceptive pain, inflammatory edema, and pyrexia at doses of 25-100 mg/kg." | 4.02 | Pharmacological evaluation of the gabapentin salicylaldehyde derivative, gabapentsal, against tonic and phasic pain models, inflammation, and pyrexia. ( Ahmad, N; Akbar, S; Amin, MU; Islam, NU; Khurram, M; Sewell, RDE; Shahid, M; Subhan, F; Ullah, I; Ullah, N; Ullah, R, 2021) |
| "Managing cancer-related pain in patients who are also pregnant compounds the challenge for adequate pain management, as studies have largely excluded this population." | 3.01 | Pharmacologic Management of Cancer-Related Pain in Pregnant Patients. ( McGinn, R; Smith, MA; Zerfas, I, 2023) |
| "Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy." | 2.55 | Neuropathic pain. ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| " Time-course data for the dose-response effects were analyzed using two-way analysis of variance and the posthoc Tukey-Kramer multiple-comparison test." | 1.40 | Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats. ( Hashimoto, R; Hosokawa, K; Mashimo, T; Nakae, A; Nakai, K, 2014) |
| "Neuropathic pain is currently an insufficiently treated clinical condition." | 1.40 | Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy. ( Hammock, BD; Inceoglu, B; Wagner, K; Yang, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zerfas, I | 1 |
| McGinn, R | 1 |
| Smith, MA | 1 |
| Gonçalves Dos Santos, G | 1 |
| Jimenéz-Andrade, JM | 1 |
| Woller, SA | 1 |
| Muñoz-Islas, E | 1 |
| Ramírez-Rosas, MB | 1 |
| Ohashi, N | 1 |
| Ferreira Catroli, G | 1 |
| Fujita, Y | 1 |
| Yaksh, TL | 1 |
| Corr, M | 1 |
| Déciga-Campos, M | 2 |
| Villafán-Gutiérrez, R | 1 |
| Espinosa-Juárez, JV | 1 |
| Jaramillo-Morales, OA | 1 |
| López-Muñoz, FJ | 2 |
| Ahmad, N | 1 |
| Subhan, F | 1 |
| Islam, NU | 1 |
| Shahid, M | 1 |
| Ullah, N | 1 |
| Ullah, R | 1 |
| Khurram, M | 1 |
| Amin, MU | 1 |
| Akbar, S | 1 |
| Ullah, I | 1 |
| Sewell, RDE | 1 |
| Davison, SN | 1 |
| García-Hernández, L | 1 |
| Navarrete-Vázquez, G | 1 |
| González-Trujano, ME | 1 |
| Nakai, K | 1 |
| Nakae, A | 1 |
| Hashimoto, R | 1 |
| Mashimo, T | 1 |
| Hosokawa, K | 1 |
| Wagner, K | 1 |
| Yang, J | 1 |
| Inceoglu, B | 1 |
| Hammock, BD | 1 |
| Nakama-Kitamura, M | 1 |
| Adães, S | 1 |
| Ferreira-Gomes, J | 1 |
| Mendonça, M | 1 |
| Almeida, L | 1 |
| Castro-Lopes, JM | 1 |
| Neto, FL | 1 |
| Colloca, L | 1 |
| Ludman, T | 1 |
| Bouhassira, D | 1 |
| Baron, R | 1 |
| Dickenson, AH | 1 |
| Yarnitsky, D | 1 |
| Freeman, R | 1 |
| Truini, A | 1 |
| Attal, N | 1 |
| Finnerup, NB | 1 |
| Eccleston, C | 1 |
| Kalso, E | 1 |
| Bennett, DL | 1 |
| Dworkin, RH | 1 |
| Raja, SN | 1 |
| Vedula, SS | 1 |
| Goldman, PS | 1 |
| Rona, IJ | 1 |
| Greene, TM | 1 |
| Dickersin, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome: a Multicenter, Randomized, Doubleblind, Placebo-controlled Study[NCT05411900] | Phase 2 | 164 participants (Anticipated) | Interventional | 2022-05-25 | Recruiting | ||
| Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety[NCT05427058] | 36 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
| Neuropathic Foot and Ankle in Rheumatoid Arthritis : Ultrasound and Nerve Conduction Study[NCT04550884] | 80 participants (Anticipated) | Observational | 2020-10-31 | Not yet recruiting | |||
| NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial[NCT04808531] | Phase 3 | 360 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for gabapentin and Nociceptive Pain
| Article | Year |
|---|---|
Pharmacologic Management of Cancer-Related Pain in Pregnant Patients.
Topics: Analgesics; Analgesics, Opioid; Cancer Pain; Duloxetine Hydrochloride; Female; Gabapentin; Humans; N | 2023 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
10 other studies available for gabapentin and Nociceptive Pain
| Article | Year |
|---|---|
The neuropathic phenotype of the K/BxN transgenic mouse with spontaneous arthritis: pain, nerve sprouting and joint remodeling.
Topics: Analgesics; Animals; Arthritis, Experimental; Female; Gabapentin; Ganglia, Spinal; Hyperalgesia; Kne | 2020 |
Synergistic interaction between haloperidol and gabapentin in a model of neuropathic nociception in rat.
Topics: Analgesics; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug | 2021 |
Pharmacological evaluation of the gabapentin salicylaldehyde derivative, gabapentsal, against tonic and phasic pain models, inflammation, and pyrexia.
Topics: Aldehydes; Analgesics; Animals; Anti-Inflammatory Agents; Antipyretics; Carrageenan; Disease Models, | 2021 |
Clinical Pharmacology Considerations in Pain Management in Patients with Advanced Kidney Failure.
Topics: Acetaminophen; Acute Pain; Analgesics, Non-Narcotic; Analgesics, Opioid; Carbamazepine; Chronic Pain | 2019 |
Antihyperalgesic activity of a novel synthesized analogue of lidocaine in diabetic rats.
Topics: Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Diabetes Complications; | 2013 |
Antinociceptive effects of mirtazapine, pregabalin, and gabapentin after chronic constriction injury of the infraorbital nerve in rats.
Topics: Adrenergic alpha-Antagonists; Amines; Analgesics; Animals; Cranial Nerve Injuries; Cyclohexanecarbox | 2014 |
Soluble epoxide hydrolase inhibition is antinociceptive in a mouse model of diabetic neuropathy.
Topics: Amines; Analgesics; Animals; Benzoates; Chronic Pain; Conditioning, Psychological; Cyclohexanecarbox | 2014 |
The distinctive significance of analgesic drugs and olfactory stimulants on learned pain in mice.
Topics: Acetaminophen; Amines; Analgesics; Animals; Conditioning, Psychological; Cyclohexanecarboxylic Acids | 2014 |
Injury of primary afferent neurons may contribute to osteoarthritis induced pain: an experimental study using the collagenase model in rats.
Topics: Amines; Analgesics; Animals; Arthritis, Experimental; Calcium Channels; Calcium Channels, L-Type; Co | 2015 |
Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.
Topics: Access to Information; Amines; Analgesics; Antimanic Agents; Authorship; Bipolar Disorder; Clinical | 2012 |